期刊
LEUKEMIA RESEARCH
卷 35, 期 1, 页码 80-86出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2010.04.010
关键词
CML; Imatinib resistance; Peg-Interferon; Philadelphia chromosome; BCR-ABL; BCR-ABL mutations
资金
- National Natural Science Funds [30670899]
- Tianjin Key Natural Science Funds [08JCZDJC19200]
- National Key Technology R&D Program in the 11th Five year Plan of China [2008BAI61B02]
This phase I/II study was designed to demonstrate the tolerance and the efficacy of a combination of pegylated interferon-alpha 2a to Imatinib mesylate (IM) 600 mg daily in cytogenetically IM-resistant but in CHR chronic phase CML patients. The combination was generally well tolerated in the 15 evaluable patients. A significant reduction of the Ph1(+) BM metaphases was observed in these poor prognosis patients, with 2 long-term CCyR including 2 MMR. After a median follow-up of 43 months, 93% of patients are alive. The addition of PegIFN alpha 2a to IM600 is feasible, and able to overcome resistance within this context. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据